Oxeia Biopharmaceuticals is a clinical-stage biotech company developing new, innovative therapeutics for mild traumatic brain injury (mTBI), known as concussion, and related neuro-metabolic dysfunction. The company has a drug, OXE103, that began a Phase 2 clinical trial in the fall of 2020. To date there are few other studies aimed at treating these patients.
